Distinguishing the Mechanisms of Tumoral Immune Response and Cutaneous Adverse Events


Checkpoint inhibitor (CPI) therapy has revolutionized cancer treatment, but generates immune-related adverse events (irAEs) that commonly include cutaneous effects. I hypothesize that the tumor response is mechanistically distinct from associated irAEs, and will test this in patient skin samples and in a novel mouse disease model. Results can be leveraged to test new treatment avenues for irAEs without diminishing the positive impact of cancer therapy

— Noah Hornick, M.D., Ph.D.

Related Articles

Crystal Aguh M.D.

Exploring Gene Expression Patterns and Biomarkers of Disease Severity in Central Centrifugal Cicatricial Alopecia

Central centrifugal cicatricial alopecia (CCCA), which has been associated with uterine fibroids, is unlike other scarring alopecias because fibrosis rather…

Read More

Characterizing the Microbiome in Postmenopausal Women with Vulvar Lichen Sclerosus

Vulvar lichen sclerosus is a chronic inflammatory condition that leads to scarring, obliteration of normal vulvar architecture, dyspareunia, and significant…

Read More

Cell Signaling Changes Induced by Surgical Debulking May Improve Response to Smoothened Inhibitor Therapy

Smoothened (SMO) inhibitors, such as vismodegib, are effective treatments for locally advanced basal cell carcinomas (BCCs). However, recurrences are frequent…

Read More